Gestational diabetes & diabetes in pregnancy
Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: A population‐based cohort study
Main finding · LGA or macrosomiaResult — go to the resultHazard ratio 0.64 95% CI 0.49–0.78Authors' conclusion
Our study suggests that, compared to initiating insulin, initiating metformin is associated with decreased risks of adverse pregnancy outcomes among women with GDM. These findings provide important real-world evidence regarding the use of metformin for GDM.
Study context
- Population
- Pregnancies of women with GDM initiating metformin or insulin between 20 weeks gestation and pregnancy end, UK, 1998–2018
- Participants
- 1,297 vs 895
- Exposure
- Metformin vs insulin initiation
- Metforminn = 1,297
- Insulinn = 895reference
- Outcome
- Composite of:
- Large for gestational age (LGA)
- Macrosomia
Methodological detailspopulation-based, inverse probability weighted, Clinical Practice Research Datalink, pregnancy register and Hospital Episode Statistics, 1998–2018
- Population-based
- Inverse probability weighted
- Clinical Practice Research Datalink, pregnancy register and Hospital Episode Statistics, 1998–2018
Main finding
LGA or macrosomia
Hazard ratio
0.64
95% CI 0.49–0.78
Metforminvs Insulin
HR 0.64 (95% CI 0.49–0.78)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| Caesarean delivery | 0.83 (0.69–0.98) | |
| Preterm birth | 0.83 (0.58–1.08) | |
| Hypertensive disorders during pregnancy (HDP) | 0.92 (0.57–1.27) | |
| SGA | 1.33 (0.67–2.00) | |
| 0.512Hazard ratio (log scale) |
Original publication
Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: A population‐based cohort study. Diabetes Obes Metab. Published 16 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →